Pay in 4 interest-free payments of $6.68 Learn more
Ships within 48 hours · Estimated delivery Aug 23 - Aug 28
Finalized independent certificate documentation is pending for this catalog record
BPC-157 Dosing in Hepatic Impairment: Evidence, Risks, and Clinical Guidance At a glance No FDA-approved formulation / BPC-157 is available only through 503A compounding pharmacies Zero published human RCTs evaluating BPC-157 in hepatic impairment populations Animal models show hepatoprotective effects against NSAID, alcohol, and toxin-induced liver damage Standard compounded dose range is 200-500 mcg/day subcutaneously or intramuscularly Suggested starting dose in hepatic impairment is 200-250 mcg/day subcutaneously Peptides are cleared primarily by proteolytic degradation, not hepatic CYP450 metabolism Liver enzyme monitoring (ALT, AST, bilirubin) recommended at baseline and every 2-4 weeks BPC-157 has shown cytoprotective effects on gastric and intestinal mucosa in over 20 animal studies The FDA has not established hepatic dosing adjustments for BPC-157 Cycle length in liver-compromised patients: 4-6 weeks with reassessment before continuation What Is BPC-157 and How Does It Work
Our team works with researchers who administer peptides daily in controlled settings
It is classified as an unapproved drug
Despite being smaller than more-established pharmaceutical players, SureNano Science operates with a lean development model and cost-efficient structure built for flexibility and development speed
doi:10.3390/nu2030299
